Telix rejigs leadership team as part of new business model
Make us a preferred source
Make us a preferred source on Google
The news: Telix Pharmaceuticals has announced new leadership appointments as part of an "internal reorganisation" of its business model.
The numbers: Telix shares edged up 0.4% to $19.94 by 10:50am following the announcement.
The context: Group chief commercial officer Richard Valeix has been appointed chief executive of Telix Therapeutics, and will lead the company's therapeutic pipeline commercialisation and business development.
The company’s Americas chief executive Kevin Richardson has been appointed CEO of Telix Precision Medicine, leading the development of the company's diagnostics, global marketing and commercial operations in the US and Canada.
Europe, Middle East and Africa (EMEA) and Asia Pacific (APAC) CEO Raphael Ortiz has expanded his remit to include Latin America regions.
The company said the restructure was part of plans to align its operations across four business units, reflecting its focus as a therapeutics-led radiopharmaceutical company committed to precision oncology.
What they said: "Telix is at an inflection point: momentum in our therapeutics business is growth, with prostate, kidney and brain cancer therapeutic candidates currently in, or advancing to, pivotal clinical trials," said Telix managing director and group CEO Christian Behrenbruch.
"Telix is evolving, and the revised business model reflects our differentiated position, harnessing the power of targeted radiation at every step of the patient journey," he said.
The source: ASX announcement
